Assessment of cisplatin-induced kidney injury using an integrated rodent platform

Toxicology and Applied Pharmacology

Volumn 268, Issue 3, 2013, Pages 352-361

  Chen, Yafei ^a   Brott, David ^a   Luo, Wenli ^a   Gangl, Eric ^a   Kamendi, Harriet ^a   Barthlow, Herbert ^a   Lengel, David ^a   Fikes, James ^a   Kinter, Lewis ^a   Valentin, Jean Pierre ^a   Bialecki, Russell ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Cardiovascular; Cisplatin; Electroencephalogram; Renal function; Renal tubular injury; Urinary biomarkers

Indexed keywords

CISPLATIN; CREATININE; GLUTATHIONE TRANSFERASE ALPHA;

ACUTE KIDNEY TUBULE NECROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTROENCEPHALOGRAM; GLOMERULUS FILTRATION RATE; HEART RATE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PARENCHYMA; KIDNEY PLASMA FLOW; MALE; NONHUMAN; PREDICTION; RAT; UREA NITROGEN BLOOD LEVEL; URINALYSIS; WISTAR RAT;

ACUTE KIDNEY INJURY; ANIMALS; BLOOD UREA NITROGEN; CISPLATIN; GLOMERULAR FILTRATION RATE; GLUTATHIONE; KIDNEY; MALE; RANDOM ALLOCATION; RATS; RATS, WISTAR;

ANIMALIA; RATTUS; RATTUS NORVEGICUS; RODENTIA;

EID: 84875641765     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.01.032     Document Type: Article

References (56)

1. Abdin A.A., Draz E.I., Sarhan N.I. Evaluation of the chemoprotective role of N-acetylcysteine on cisplatin-induced nephrotoxicity: new aspect of an old drug. Int. J. Pharmacol. 2008, 4:339-351.
2. Agarwal R. Rapid microplate method for PAH estimation. Am. J. Physiol. Ren. 2002, 283:F236-F241.
3. Altena R., Hummel Y.M., Nuver J., Smit A.J., Lefrandt J.D., de Boer R.A., Voors A.A., van den Berg M.P., de Vries E.G., Boezen H.M., Gietema J.A. Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. Ann. Oncol. 2011, 10:2286-2293.
4. Anonymous Guidance for Industry: Safety Pharmacology Studies for Human Pharmaceuticals 2001, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER).
5. Anonymous Final Report on the Pilot Joint EMEA/FDA VXDs Experience on Qualification of Nephrotoxicity Biomarkers 2008, European Medicines Agency (EMEA).
6. Anonymous FDA, European Medicines Agency to Consider Additional Test Results When Assessing New Drug Safety 2008, Food and Drug Administration (FDA).
7. Anonymous Record of the Consultation on Pharmacogenomics/Biomarkers for Drug-induced Kidney Injury Biomarkers May 31 2010 2010, Pharmaceutical and Medical Device Agency (PMDA).
8. Bastlund J.F., Jennumb P., Mohapel P., Vanessa V., Watson W.P. Measurement of cortical and hippocampal epileptiform activity in freely moving rats by means of implantable radiotelemetry. J. Neurosci. Methods 2004, 138:65-72.
9. Beckett G.J., Hayes J.D. Glutathione S-transferases: biomedical applications. Adv. Clin. Chem. 1993, 30:281-380.
10. Bonventre J.V., Vaidya V.S., Schmouder R., Feig P., Dieterle F. Next-generation biomarkers for detecting kidney toxicity. Nat. Biotechnol. 2010, 28:436-440.
11. Burger H., Loos W.J., Eechoute K., Verweij J., Mathijssen R.H., Wiemer E.A. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist. Updates 2011, 14:22-34.
12. Chen Y., Brott D., Bentley P., Thurman D., Kinter L., Bialecki R.A. Urinary biomarkers for the early prediction of cisplatin-induced changes in kidney function and injury in rats. Toxicologist 2011, 120(S2):742.
13. Christensen E., Birn H., Rippe B., Maunsbach A.B. Controversies in nephrology: renal albumin handling, facts, and artifacts. Kidney Int. 2007, 72:1192-1194.
14. Dickey D.T., Muldoon L.L., Doolittle N.D., Peterson D.R., Kraemer D.F., Neuwelt E.A. Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models. Cancer Chemother. Pharmacol. 2008, 62:235-241.
15. Fischer P.A., Bogoliuk C.B., Ramirez A.J., Sánchez R.A., Masnatta L.D. A new procedure for evaluation of renal function without urine collection in rat. Kidney Int. 2000, 58:1336-1341.
16. Gautier J.C., Riefke B., Walter J., Kurth P., Mylecraine L., Guilpin V., Barlow N., Gury T., Hoffman D., Ennulat D., Schuster K., Harpur E., Pettit S. Evaluation of novel biomarkers of nephrotoxicity in two strains of rat treated with Cisplatin. Toxicol. Pathol. 2010, 38:943-956.
17. Haase M., Bellomo R., Devarajan P., Schlattmann P., Haase-Fielitz A. NGAL Meta-analysis Investigator Group Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am. J. Kidney Dis. 2009, 54:1012-1024.
18. Hanada K., Ninomiya K., Ogata H. Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin. J. Pharm. Pharmacol. 2000, 52:1345-1353.
19. Hoffmann D., Fuchs T.C., Henzler T., Matheis K.A., Herget T., Dekant W., Hewitt P., Mally A. Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity. Toxicology 2010, 277:49-58.
20. Ichimura T., Hung C.C., Yang S.A., Stevens J.L., Bonventre J.V. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am. J. Physiol. Ren. 2004, 286:F552-F563.
21. Institute of Laboratory Animal Research (ILAR), Commission on Life Sciences, National Research Council Guide for the Care and Use of Laboratory Animals 1996, National Academy Press, Washington DC.
22. Kamendi H., Brott D., Chen Y., Fonck C., Litwin D., Lengel D.J., Bialecki R.A. Combining radio telemetry and automated blood sampling: a novel approach for integrative pharmacology and toxicology studies. J. Pharmacol. Toxicol. Methods 2010, 62:30-39.
23. Kellum J.A., Levin N., Bouman C., Lameire N. Developing a consensus classification system for acute renal failure. Curr. Opin. Crit. Care 2002, 8:509-514.
24. Kern W., Braess J., Kaufmann C.C., Wilde S., Schleyer E., Hiddemann W. Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection. Anticancer Res. 2000, 20:3679-3688.
25. Koch Nogueira P.C., Hadj-Aïssa A., Schell M., Dubourg L., Brunat-Mentigny M., Cochat P. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatr. Nephrol. 1998, 12:572-575.
26. Kodera Y., Isobe K., Yamauchi M., Kondo K., Akiyama S., Ito K., Nakashima I., Takagi H. Expression of glutathione-S-transferases alpha and pi in gastric cancer: a correlation with cisplatin resistance. Cancer Chemother. Pharmacol. 1994, 34:203-208.
27. Krarup-Hansen A., Helweg-Larsen S., Schmalbruch H., Rørth M., Krarup C. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007, 130:1076-1088.
28. Launay-Vacher V., Rey J.B., Isnard-Bagnis C., Deray G., Daouphars M. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother. Pharmacol. 2008, 61:903-909.
29. Littell R., Milliken G., Stroup W., Wolfinger R., Schabenberger O. SAS for Mixed Models 2006, SAS Institute Inc., Cary, NC, USA. 2nd edition.
30. Litwin D.C., Lengel D.J., Kamendi H.W., Bialecki R.A. An integrative pharmacological approach to radio telemetry and blood sampling in pharmaceutical drug discovery and safety assessment. Biomed. Eng. Online 2011, 10:5.
31. Lorenz J.N., Gruenstein E. A simple, nonradioactive method for evaluating single-nephron filtration rate using FITC-inulin. Am. J. Physiol. Ren. 1999, 276:F172-F177.
32. Luyckx V.A., Naicker S. Acute kidney injury associated with the use of traditional medicines. Nat. Clin. Pract. Nephrol. 2008, 4:664-671.
33. Makhija S., Sabbatini P., Aghajanian C., Venkatraman E., Spriggs D.R., Barakat R. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look. Gynecol. Oncol. 2000, 79:28-32.
34. McCulloch C.E., Searle S.R. Generalized, Linear, and Mixed Models 2001, John Wiley & Sons, Inc., (Copyright© 2001).
35. Meng M., Kuntz R., Fontanet A., Bennett P.K. A novel approach to quantify unbound cisplatin, carboplatin, and oxaliplatin. Human Plasma Ultrafiltrate by Measuring Platinum-DDTC Complex Using LC/MS/MS Tandem Labs, Salt Lake City, Utah 2006 ASMS Conference 2006, (http://www.tandemlabs.com/documents/ASMS_06_Min_lowres.pdf).
36. Naughton C.A. Drug-induced nephrotoxicity. Am. Fam. Physician 2008, 78:743-750.
37. Pabla N., Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008, 73:994-1007.
38. Qi Z., Whitt I., Mehta A., Jin J., Zhao M., Harris R.C., Fogo A.B., Breyer M.D. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am. J. Physiol. Ren. 2004, 286:F590-F596.
39. Ravindra P., Bhiwgade D.A., Kulkarni S., Rataboli P.V., Dhume C.Y. Cisplatin induced histological changes in renal tissue of rat. J. Cell Anim. Biol. 2010, 4:108-111.
40. Redfern W.S., Ewart L., Hammond T.G., Bialecki R., Kinter L., Lindgren S., Pollard C.E., Roberts R., Rolf M.G., Valentin J.-P. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. Toxicologist 2010, 114(S1):1081.
41. Rhoades R., Bell D.R. Medical Physiology: Principles for Clinical Medicine. CHAPTER 22 Kidney Function 2008, 391-418. 3rd edition.
42. Russell W.M.S., Burch R.L. The Principles of Humane Experimental Technique 1959, Methuen, London, (Reprinted by UFAW, 1992).
43. Safirstein R., Miller P., Guttenplan J.B. Uptake and metabolism of cisplatin by rat kidney. Kidney Int. 1984, 25:753-758.
44. Sheehan D.C., Hrapchak B.B. Theory and Practice of Histotechnology 1980, C.V. Mosby Company, St Louis, MO. 2nd edition.
45. Siddik Z.H., Newell D.R., Boxall F.E., Harrap K.R. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem. Pharmacol. 1987, 36:1925-1932.
46. Sturgeon C., Sam A.D., Law W.R. Rapid determination of glomerular filtration rate by single-bolus inulin: a comparison of estimation analyses. J. Appl. Physiol. 1998, 84:2154-2162.
47. Tonomura Y., Tsuchiya N., Torii M., Uehara T. Evaluation of the usefulness of urinary biomarkers for nephrotoxicity in rats. Toxicology 2010, 273:53-59.
48. Traynor J., Mactier R., Geddes C.C., Fox J.G. How to measure renal function in clinical practice. Br. Med. J. 2006, 333:733-737.
49. Urbschat A., Obermüller N., Haferkamp A. Biomarkers of kidney injury. Biomarkers 2011, 16(Suppl. 1):S22-S30.
50. Vaidya V.S., Ferguson M.A., Bonventre J.V. Biomarkers of acute kidney injury. Annu. Rev. Pharmacol. Toxicol. 2008, 48:463-493.
51. Valentin J.P., Bialecki R., Ewart L., Hammond T., Leishmann D., Lindgren S., Martinez V., Pollard C., Redfern W., Wallis R. A framework to assess the translation of safety pharmacology data to humans. J. Pharmacol. Toxicol. Methods 2009, 60:152-158.
52. Winston J.A., Safirstein R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am. J. Physiol. Ren. 1985, 249:F490-F496.
53. Wolfgang G.H., Dominick M.A., Walsh K.M., Hoeschele J.D., Pegg D.G. Comparative nephrotoxicity of a novel platinum compound, cisplatin, and carboplatin in male Wistar rats. Fundam. Appl. Toxicol. 1994, 22:73-79.
54. Yao X., Panichpisal K., Kurtzman N., Nugent K. Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. 2007, 334:115-124.
55. Yu Y., Jin H., Holder D., Ozer J.S., Villarreal S., Shughrue P., Shi S., Figueroa D.J., Clouse H., Su M., Muniappa N., Troth S.P., Bailey W., Seng J., Aslamkhan A.G., Thudium D., Sistare F.D., Gerhold D.L. Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nat. Biotechnol. 2010, 28:470-477.
56. Zhang J., Goering P.L., Espandiari P., Shaw M., Bonventre J.V., Vaidya V.S., Brown R.P., Keenan J., Kilty C.G., Sadrieh N., Hanig J.P. Differences in immunolocalization of Kim-1, RPA-1, and RPA-2 in kidneys of gentamicin-, cisplatin-, and valproic acid-treated rats: potential role of iNOS and nitrotyrosine. Toxicol. Pathol. 2009, 37:629-643.